Althea Group (ASX:AGH) - CEO, Joshua Fegan
CEO, Joshua Fegan
Source: The Green Fund
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • In an Australian first, pharmaceutical company Althea Group (AGH) can now sell medicinal cannabis online
  • An update to the company’s Althea Concierge platform allows patients to purchase medicinal cannabis products online and get it delivered to their door
  • This update will eliminate the need for multiple visits to the doctor and the pharmacy
  • CEO Josh Fegan believes contactless sales are the biggest development so far for the medicinal cannabis industry in Australia
  • Althea is up 8.7 per cent on the market today and is trading for 37.5 cents each

In an Australian first, pharmaceutical company Althea Group (AGH) can now sell medicinal cannabis online.

The company’s Althea Concierge platform has now been registered with the Therapeutic Goods Administration (TGA) as a medical device.

The platform was first launched in Australia in Septemeber 2018 and provides medical education and clinical evidence for healthcare professionals looking to prescribe medicinal cannabis.

Althea Concierge will allow doctors to prescribe medicinal cannabis products via the platform and patients can pay for their prescriptions online. This will eliminate the need for multiple visits to the doctor and the pharmacy.

Patients can download Althea Concierge app on their smartphones, and the app will deliver customised dosage reminders to the patient, helping them record their medical usage.

Althea CEO Josh Fegan is very excited about the update to the Althea Concierge platform.

“The ability for contactless sales is probably the biggest development yet for medicinal cannabis in Australia,” he said.

“You need to have a lot more than just a quality product in the highly regulated prescription cannabis space, and Althea’s ongoing investment in technology, provides us with a premium value proposition that we believe none of our competitors possesses,” he added

The company is also looking to update Althea Concierge in the U.K. over the next few months.

Althea is up 8.70 per cent on the market this morning and is trading for 37.5 cents each at 1:07 pm AEST.

AGH by the numbers
More From The Market Online
The Market Online Video

Recce progresses testing of gel to treat bacterial skin infections

Recce Pharmaceuticals Ltd has reached an important milestone in testing of its R327G gel to treat…
Burn wound care

Orthocell wins first international approval for nerve repair product

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences…
Map showing Valeriepieris Circle - a relatively small area of Earth’s surface that contains half the human population.

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical…
The Market Online Video

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical…